• ქართული
  • English
  • Eli Lilly cuts 2019 forecast on trial failure, Loxo deal

    Eli Lilly and Co cut its 2019 profit forecast on Wednesday, hit by a recent trial failure of conditionally approved cancer treatment Lartruvo and costs related to its pending acquisition of Loxo Oncology.

    Market Quotes by TradingView